156 related articles for article (PubMed ID: 17725926)
1. Epidermal growth factor receptor inhibitor-related folliculitis.
Tangri N; Al Hammadi A; Gerstein W
Dermatitis; 2007 Sep; 18(3):178-9. PubMed ID: 17725926
[No Abstract] [Full Text] [Related]
2. Erlotinib-induced scalp perifolliculitis.
Rallis E; Petronic-Rosic V; Korfitis C
Skinmed; 2012; 10(2):70-1. PubMed ID: 22545319
[TBL] [Abstract][Full Text] [Related]
3. Valuable lessons from treatment of non-small cell lung cancer with erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.
Shrimali RK; Correa PD; Rizwanullah M
BMJ Case Rep; 2008; 2008():bcr0620080075. PubMed ID: 21716815
[No Abstract] [Full Text] [Related]
4. Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment.
Tan AR; Steinberg SM; Parr AL; Nguyen D; Yang SX
Ann Oncol; 2008 Jan; 19(1):185-90. PubMed ID: 17878175
[TBL] [Abstract][Full Text] [Related]
5. Acitretin for treatment of EGFR inhibitor-induced cutaneous toxic effects.
Pomerantz RG; Chirinos RE; Falo LD; Geskin LJ
Arch Dermatol; 2008 Jul; 144(7):949-50. PubMed ID: 18645156
[No Abstract] [Full Text] [Related]
6. Purpuric Drug Eruptions Caused by Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer: A Clinicopathologic Study of 32 Cases.
Cho YT; Chen KL; Sheen YS; Yang CW; Liau JY; Cheng YP; Chu CY
JAMA Dermatol; 2017 Sep; 153(9):906-910. PubMed ID: 28538945
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor.
Santoro F; Cozzani E; Parodi A
J Dermatolog Treat; 2006; 17(3):160-1. PubMed ID: 16854757
[TBL] [Abstract][Full Text] [Related]
8. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
Eames T; Landthaler M; Karrer S
Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
[No Abstract] [Full Text] [Related]
9. Acneiform reaction to erlotinib.
Schalock PC; Zug KA
Dermatitis; 2007 Dec; 18(4):230-1. PubMed ID: 18021605
[TBL] [Abstract][Full Text] [Related]
10. [Targeted therapies. New hopes, new challenges].
Barlési F
Rev Mal Respir; 2008 Jun; 25(6):661-2. PubMed ID: 18772823
[No Abstract] [Full Text] [Related]
11. Interstitial lung disease arising from erlotinib treatment in a Caucasian patient.
Bugés C; Carcereny E; Moran T; Cardona AF; Reguart N; Capdevila L; Cros S; Rosell R
Clin Lung Cancer; 2015 Mar; 16(2):e1-3. PubMed ID: 25550194
[No Abstract] [Full Text] [Related]
12. Folliculitis-perifolliculitis related to erlotinib therapy spares previously irradiated skin.
Acharya J; Lyon C; Bottomley DM
J Am Acad Dermatol; 2009 Jan; 60(1):154-7. PubMed ID: 19103369
[TBL] [Abstract][Full Text] [Related]
13. [Cutaneous reactions due to the use of epidermal growth factor receptor inhibitors: two case reports].
Rodarte CM; Abdallah OA; Barbosa NF; Koch Lde O; Resende UM
An Bras Dermatol; 2009; 84(6):667-70. PubMed ID: 20191181
[TBL] [Abstract][Full Text] [Related]
14. Dimorphic cutaneous manifestation of a toxic eruption due to erlotinib therapy.
Campbell TM; Brown CW
J Drugs Dermatol; 2008 Dec; 7(12):1161-3. PubMed ID: 19137770
[TBL] [Abstract][Full Text] [Related]
15. Follicular rash during therapy with erlotinib (Tarceva).
Gerdes S; Mrowietz U
J Dtsch Dermatol Ges; 2006 Oct; 4(10):855-7. PubMed ID: 17010175
[TBL] [Abstract][Full Text] [Related]
16. [Cutaneous side effects of EGF receptor inhibitors].
Nassar D; Soutou B; Aractingi S
Bull Cancer; 2009 Dec; 96 Suppl():S85-91. PubMed ID: 20034874
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer.
Byrne BJ; Garst J
Curr Oncol Rep; 2005 Jul; 7(4):241-7. PubMed ID: 15946581
[TBL] [Abstract][Full Text] [Related]
18. Rosaceiform eruption induced by erlotinib.
Patrizi A; Bianchi F; Neri I
Dermatol Ther; 2008 Oct; 21 Suppl 2():S43-5. PubMed ID: 18837734
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
20. Targeting the epidermal growth factor receptor in non-small cell lung cancer.
Steins MB; Reinmuth N; Bischoff H; Kindermann M; Thomas M
Onkologie; 2010; 33(12):704-9. PubMed ID: 21124044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
